anti-IL-22/IL-23 bispecific antibody(Earendil Labs)

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug Nameanti-IL-22/IL-23 bispecific antibody(Earendil Labs)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of Actionanti-Interleukin-22Anti-Interleukin-23

TargetsInterleukin-22Interleukin-23

Therapy Area/IndicationsAutoimmune DiseasesPsoriasisSkin Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesEarendil Labs

China Registration ClassN/A

Develop Information

Active CompaniesEarendil Labs

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesPsoriasisSkin Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A